BRMS1 and neoplasm: Interestingly, in addition to correlating with the pathological staging in breast cancer and NSCLC [103,104], the BRMS1 (breast cancer metastasis suppressor 1) promoter methylation represents a relevant example of prognostic biomarker detectable by liquid biopsies in both cfDNA [104] and CTCs (circulating tumor cells) [105].